Monoclonal antibodies light up rat tissue culture

I wrote about the cancer drug ipilimumab last year, which has been hailed as miraculous by some. The drug has been through Phase 3 clinical trials and results will be presented on June 6 at the annual meeting of the American Society of Clinical Oncology (ASCO).

Meanwhile, following announcements of the miracle cure in three men having prostate cancer, ipilimumab has also been show to be modestly effect against lung cancer, according to the company.

Ipilimumab works by targeting an inhibitor of the immune system called CTLA-4 (cytotoxic T lymphocyte-associated antigen 4) and subsequently boosting the response of the killer T-cells. It belongs to the highly promising monoclonal antibody field of therapeutics.

Quote from a press release sounds like the company is excited:

“We are excited by the potential of immuno-oncology, an entirely new paradigm in the treatment of multiple types of cancer in which a patient’s own immune system is activated to fight cancer cells,” said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb.

“We are leading the way with ipilimumab, the most advanced investigational compound in our immuno-oncology portfolio, in testing this new paradigm and we look forward to presenting results from the ipilimumab clinical development program at this year’s American Society of Clinical Oncology Annual Meeting.”

But while the promise of the basic science is cool, it’ll be difficult to draw conclusions about the real-world application of the drug until the results are formally presented and peer reviewed.